Related Experiment Video
Updated: Feb 9, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery
Ayca Yildiz-Peköz1, Ozlem Akbal1, S Hande Tekarslan1
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Abstract:
Pneumonia is a bacterial lower respiratory tract infection that has a high morbidity rate. The gram-negative pathogen Pseudomonas aeruginosa is a significant cause of nosocomial infections and ventilator-associated pneumonias and is mainly treated by carbapenems. Doripenem is a carbapenem drug, which has a broad-spectrum antibacterial activity. The aim of this study was to develop doripenem-loaded chitosan microparticles for pulmonary administration to provide more efficient treatment for pneumonia. Ionotropic gelation and the spray-drying method were used to obtain doripenem-loaded chitosan microparticles with different lactose, trehalose, and L-leucine concentrations. Physicochemical characteristics, in vitro drug release properties, and aerodynamics properties were investigated and in vitro antimicrobial susceptibility tests of the formulations were performed. Assessment of aerodynamic properties of the powders, including Mass Median Aerodynamic Diameter, size distribution, and fine particle fraction (FPF), were performed using a Next Generation Impactor. Cytotoxicity of the fabricated microparticles was assessed using the Calu-3 cell airway epithelial cell line. Optimum microparticles were produced using a combination of ionotropic gelation and spray-drying methods. Spray-dried microparticle production yield was relatively high (74.03% ± 3.88% to 98.23% ± 1.70%). Lactose, trehalose, and L-leucine were added to the formulation to prevent aggregation produced by the ionotropic gelation spray-drying method. Each formulation's encapsulation efficiency was above 78.98% ± 2.37%. The doripenem-loaded microparticle mean diameter ranged from 3.8 ± 0.110 to 6.9 ± 0.090 μm. Microparticles with 20% (w/w) L-leucine had the highest FPF ratio indicating the best aerosolization properties of the formulations. The efficacy of the formulations as an antibacterial agent was increased by forming doripenem-loaded microparticles compared to blank microparticles. P. aeruginosa showed the same susceptibility to all doripenem-loaded microparticle formulations. Cell viability of microparticles was between 70% ± 0.08% and 90% ± 0.04% at 0.5 and 10 mg/mL concentration, respectively. Doripenem-loaded microparticles, produced using a combination of ionotropic gelation and spray-drying methods, are suitable for pulmonary drug delivery based on their particles size, zeta potential, cytotoxicity and high production yield. To our knowledge, this is the first study that microparticles containing doripenem were produced and characterized.
Insights
This study developed doripenem-loaded chitosan microparticles for pneumonia treatment via pulmonary delivery. The novel microparticles demonstrated suitable aerodynamic properties and efficacy against Pseudomonas aeruginosa.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Engineering
- Infectious Diseases
Background:
- Pneumonia, a severe lower respiratory tract infection, often necessitates treatment with carbapenems.
- Pseudomonas aeruginosa is a key pathogen in hospital-acquired and ventilator-associated pneumonias.
- Doripenem, a broad-spectrum carbapenem, is a primary therapeutic agent.
Purpose of the Study:
- To develop doripenem-loaded chitosan microparticles for efficient pulmonary administration in pneumonia treatment.
- To characterize the physicochemical, aerodynamic, and in vitro antimicrobial properties of these microparticles.
Main Methods:
- Doripenem-loaded chitosan microparticles were fabricated using ionotropic gelation and spray-drying techniques.
- Formulations incorporated varying concentrations of lactose, trehalose, and L-leucine to optimize properties.
- Aerodynamic performance was assessed using a Next Generation Impactor, and cytotoxicity was evaluated on Calu-3 cells.
Main Results:
- High production yields (74.03%–98.23%) and encapsulation efficiencies (>78.98%) were achieved.
- Microparticle size ranged from 3.8–6.9 μm, with optimal aerosolization observed for formulations containing 20% L-leucine.
- In vitro studies confirmed enhanced antibacterial efficacy and good cell viability (70%–90%).
Conclusions:
- Doripenem-loaded chitosan microparticles produced via combined ionotropic gelation and spray-drying are suitable for pulmonary drug delivery.
- These microparticles exhibit favorable particle size, zeta potential, cytotoxicity, and production yield.
- This represents the first characterization of doripenem-containing microparticles for potential therapeutic applications.
Related Concept Videos
Impact Loading
In cases of elastic deformation,...
Distributed Loads
For example, consider a bookshelf filled with books stacked vertically adjacent to each other. The weight of the books is evenly distributed over the length of the shelf. As a result, the pressure at different locations on the surface of the...
Eccentric Loading
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

